^
    3ms
    Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) (clinicaltrials.gov)
    P1/2, N=204, Recruiting, Evopoint Biosciences Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • XNW5004
    5ms
    Study of XNW5004 Tablet in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) (clinicaltrials.gov)
    P1/2, N=204, Not yet recruiting, Evopoint Biosciences Inc.
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • XNW5004
    1year
    XNW5004: a novel EZH2 inhibitor efficacious in multiple cancer xenograft models as a single agent and in combination studies (AACR 2023)
    In summary, XNW5004 is a potent EZH2 inhibitor with promising efficacy, pharmacokinetic and safety properties. XNW5004 is expected to be a potent therapeutic candidate in cancer treatment and is now in Phase II clinical trial for both liquid and solid tumors.
    Preclinical • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    AR (Androgen receptor) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    EZH2 mutation • AR expression • EZH2 Y641F • EZH2 Y641 • EZH2 overexpression
    |
    XNW5004